The landscape of biomedical innovation is often defined by those willing to venture into the "uncharted territories" of human biology—researchers who look past incremental progress to challenge fundamental scientific paradigms. This month, the National Institutes of Health (NIH) recognized three such visionaries from the Broad Institute of MIT and Harvard, awarding them prestigious honors under the NIH’s High-Risk, High-Reward Research Program.
Broad Institute core members Erin Chen and Sam Peng have been named recipients of the NIH Director’s New Innovator Award, a distinction reserved for early-career scientists who demonstrate exceptional creativity and the potential to revolutionize their respective fields. Meanwhile, JT Neal, an institute scientist and director of systems genomics at the Broad, has been awarded the NIH Director’s Transformative Research Award—a grant specifically designed to support projects that aim to overturn or create foundational shifts in biomedical science.
These three investigators are among an elite cohort of 58 researchers nationwide selected for the 2024 program, which collectively distributed over $237 million to advance bold, unconventional approaches to the most pressing challenges in medicine.
Main Facts: The 2024 NIH High-Reward Cohort
The High-Risk, High-Reward Research Program is a unique arm of the NIH Common Fund. Unlike traditional grant mechanisms that often favor projects with highly predictable outcomes, this program actively seeks out proposals that carry inherent risk but offer the potential for high-impact breakthroughs.
The Awardees
- Dr. Erin Chen: A core institute member at the Broad, assistant professor of biology at MIT, and attending dermatologist at Massachusetts General Hospital. Her work focuses on the intersection of dermatology and immunology, specifically the role of the skin microbiome.
- Dr. Sam Peng: A core institute member at the Broad and assistant professor of chemistry at MIT. His research aims to push the boundaries of biophysical chemistry through the development of ultra-sensitive imaging technologies.
- Dr. JT Neal: An institute scientist and investigator in the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at the Broad. His work represents a massive scale-up in functional genomics and drug discovery technology.
Chronology: A Trajectory of Scientific Excellence
The success of these three researchers is not an isolated event but rather the culmination of years of rigorous academic and professional preparation.
Erin Chen: Bridging Clinic and Lab
Dr. Chen’s ascent began with her dual focus on clinical dermatology and molecular biology. Since joining the Broad in 2023, she has leveraged her position as a practicing clinician at Mass General to inform her laboratory research. Her transition to the Broad was strategic, placing her at the nexus of computational biology and immunology.
Sam Peng: Expanding the Chemical Frontier
Joining the Broad in 2022, Dr. Peng brought with him a background in chemical physics and molecular engineering. His trajectory reflects a modern trend in science where chemistry and microscopy converge to solve biological puzzles. By developing tools to "see" the invisible mechanisms of cellular signaling, he has positioned himself as a pivotal figure in modern structural biology.
JT Neal: A Decade of Innovation
JT Neal’s history at the Broad spans nearly ten years, marking him as a veteran of the institute’s systems genomics initiatives. His career is characterized by the development of "massively parallel" technologies. Having previously received the NIH New Innovator Award in 2021, his current Transformative Research Award represents a natural evolution of his previous successes in immuno-oncology and functional genomics.
Supporting Data: The Mechanics of Innovation
The grants awarded to Chen, Peng, and Neal are not merely accolades; they are fuel for specific, highly technical scientific missions.
The Skin-Immune Interface (Chen)
Dr. Chen’s research explores a counterintuitive phenomenon: how the bacteria inhabiting our skin can trigger T-cell responses that protect against disease without the collateral damage of inflammation. Conventional wisdom often treats the microbiome as a bystander or a source of irritation. Chen’s work seeks to map the precise molecular signals that allow the immune system to "tolerate" commensal bacteria while remaining alert to pathogens. This could pave the way for a new class of topical immunotherapies for skin diseases.
Decoding GPCR Signaling (Peng)
G-protein-coupled receptors (GPCRs) are the "gatekeepers" of the cell, mediating the actions of hormones and neurotransmitters. Despite their importance, the real-time dynamics of how these receptors signal remain difficult to observe. Dr. Peng’s project involves building novel single-molecule microscopy techniques to capture these transient signaling events. By visualizing these mechanisms at a level of detail previously unattainable, his research aims to provide the structural insights necessary to design more precise, effective therapeutics for a wide spectrum of disorders, from cardiovascular disease to neurological conditions.
The "Encore" Platform (Neal)
Dr. Neal’s project, titled "Encore," is perhaps the most ambitious of the three. It aims to solve the "n-of-1" problem in rare disease research. Rare genetic diseases are notoriously difficult to treat because the patient populations are small and the biological mechanisms are poorly understood. Encore is an experimental and computational engine that will screen thousands of drugs against hundreds of disease-associated phenotypes simultaneously. By testing over 1.6 million drug-disease combinations in parallel, the platform seeks to repurpose existing medications for diseases that currently have no therapeutic options.
Official Responses and Perspectives
The NIH, through the Common Fund, has emphasized that these awards are essential for maintaining the United States’ competitive edge in scientific discovery.
"The High-Risk, High-Reward Research Program serves as a catalyst for innovation," said a representative for the NIH. "When we support investigators like Chen, Peng, and Neal, we are not just funding a single project; we are investing in the potential to shift the entire trajectory of how we understand disease biology and drug discovery."
Broad Institute leadership has similarly lauded the achievements. "These awards reflect the Broad’s commitment to tackling the most challenging, high-impact problems in science," noted an internal statement from the institute. "Erin, Sam, and JT represent the next generation of scientific leadership—researchers who are unafraid to challenge established norms in the pursuit of transformative knowledge."
Implications: The Future of Medicine
The work supported by these awards carries profound implications for the future of healthcare.
Rethinking Therapeutic Development
The shift toward massively parallel drug screening—as pioneered by JT Neal—suggests a future where drug discovery is less of a "trial-and-error" process and more of a systematic, computational undertaking. If successful, Encore could democratize access to treatments for thousands of patients with rare genetic conditions who have historically been overlooked by traditional pharmaceutical pipelines.
Precision Immunology and Biophysics
Dr. Chen’s work suggests a future of "microbiome-informed medicine," where physicians might prescribe treatments that modulate the skin’s native bacteria to manage chronic inflammation, reducing the reliance on immunosuppressive systemic drugs. Simultaneously, Dr. Peng’s development of single-molecule imaging provides the "eyes" for the next generation of drug design, allowing chemists to create molecules that fit into receptor sites with unprecedented accuracy, minimizing side effects.
A Culture of Risk
The broader implication of these awards is the validation of the "high-risk" research culture. By providing a safety net for researchers to pursue ambitious, long-term goals, the NIH is ensuring that science does not become stagnant. The success of these three Broad investigators reinforces the idea that the most significant leaps in medicine often come from researchers who are willing to risk failure for the possibility of profound, life-saving discovery.
As these projects get underway, the scientific community will be watching closely. Whether it is uncovering the secret language of the skin microbiome, witnessing the real-time choreography of cellular receptors, or running a million-plus drug screens in parallel, the work of Chen, Peng, and Neal serves as a beacon of progress in a rapidly evolving field. They are not merely conducting experiments; they are drafting the blueprints for the medicine of the next century.
About the Author
